-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the official website of NMPA shows that Nanjing Chia Tai Tianqing has entered the administrative approval stage with imitation of Category 3 sitagliptin and metformin sustained-release tablets, and is expected to be approved for listing in the near future
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
Sitagliptin phosphate is an oral, highly selective DPP-4 small molecule inhibitor, and metformin is the first-line drug recommended by the current diabetes medication guidelines
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
According to data from Menet.
com, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
com, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
Whether in medical institutions or physical pharmacies, the sitagliptin and metformin market has shown a significant upward trend
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
Sales of sitagliptin and metformin in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Although single-prescription preparations such as metformin and acarbose are still market leaders in oral hypoglycemic drugs, the market scale of compound hypoglycemic preparations has gradually increased in recent years
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
2020 China City Entity Pharmacy Terminal Compound Hypoglycemic Agent Generic Name TOP3
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
At present, sitagliptin and metformin products that have been marketed in China include sitagliptin and metformin tablets (I), sitagliptin and metformin tablets (II), and sitagliptin and metformin tablets (Ⅲ)
.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
Data source: Mi Neiwang database, NMPA
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 297 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, the official website of NMPA shows that Nanjing Chia Tai Tianqing has entered the administrative approval stage with imitation of Category 3 sitagliptin and metformin sustained-release tablets, and is expected to be approved for listing in the near future
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
Sitagliptin phosphate is an oral, highly selective DPP-4 small molecule inhibitor, and metformin is the first-line drug recommended by the current diabetes medication guidelines
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
According to data from Menet.
com, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
com, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
Whether in medical institutions or physical pharmacies, the sitagliptin and metformin market has shown a significant upward trend
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
Sales of sitagliptin and metformin in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Although single-prescription preparations such as metformin and acarbose are still market leaders in oral hypoglycemic drugs, the market scale of compound hypoglycemic preparations has gradually increased in recent years
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
2020 China City Entity Pharmacy Terminal Compound Hypoglycemic Agent Generic Name TOP3
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
At present, sitagliptin and metformin products that have been marketed in China include sitagliptin and metformin tablets (I), sitagliptin and metformin tablets (II), and sitagliptin and metformin tablets (Ⅲ)
.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
Data source: Mi Neiwang database, NMPA
Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 297 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Recently, the official website of NMPA shows that Nanjing Chia Tai Tianqing has entered the administrative approval stage with imitation of Category 3 sitagliptin and metformin sustained-release tablets, and is expected to be approved for listing in the near future
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
.
Sitagliptin and metformin is a compound hypoglycemic preparation.
In 2020, the total terminal sales of Chinese public medical institutions and physical pharmacies in Chinese cities will reach 276 million yuan
.
Sitagliptin phosphate is an oral, highly selective DPP-4 small molecule inhibitor, and metformin is the first-line drug recommended by the current diabetes medication guidelines
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
.
Studies have shown that the combined use of sitagliptin phosphate and the traditional hypoglycemic drug metformin can control blood sugar more effectively and steadily
.
According to data from Menet.
com, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
Hospital hospital hospital pharmacy pharmacy pharmacycom, in 2020, Merck’s Sitagliptin and Metformin tablets had global sales of US$1.
971 billion; in 2020, China’s urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) and The total sales of sitagliptin and metformin in physical pharmacies in cities in China reached 276 million yuan
.
Whether in medical institutions or physical pharmacies, the sitagliptin and metformin market has shown a significant upward trend
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
.
In 2020, the sales of sitagliptin and metformin in physical pharmacies in Chinese cities will be 95.
01 million yuan, a year-on-year increase of 55.
59%.
It is expected that the sales will exceed 100 million yuan in 2021
.
Sales of sitagliptin and metformin in physical pharmacies in cities in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
Although single-prescription preparations such as metformin and acarbose are still market leaders in oral hypoglycemic drugs, the market scale of compound hypoglycemic preparations has gradually increased in recent years
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
.
Among them, metformin glibenclamide, sitagliptin metformin, and pioglitazone metformin are the leading compound hypoglycemic preparations in physical pharmacies
.
2020 China City Entity Pharmacy Terminal Compound Hypoglycemic Agent Generic Name TOP3
Source: Mi Nei.
com, China's urban physical pharmacy terminal competition pattern
com, China's urban physical pharmacy terminal competition pattern
At present, sitagliptin and metformin products that have been marketed in China include sitagliptin and metformin tablets (I), sitagliptin and metformin tablets (II), and sitagliptin and metformin tablets (Ⅲ)
.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
Enterprise business enterprise.
Sitagliptin Metformin Sustained Release Tablets No companies approved the listing, NJCTT go through the product registration status has been changed to "the approval", it will be deemed approved if the smooth over commentary, won China's first imitation
.
Data source: Mi Neiwang database, NMPA
Data source: Mi Neiwang database, NMPA Note: Meinenet China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 297 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.
.
The above sales are calculated based on the average retail price of the product at the terminal
.
